British Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology
5 years ago

Urinary miR-155-5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation

Irene Silva, Maaren Matz, Mercè Brunet, Irene Aliart, Claudia Sommerer, Lluis Guirado, Martin Zeier, Beatriz Bardaji, Olesja Rissling, Klemens Budde, Olga Millán
Background and Purpose MicroRNAs (miRNAs) may be useful biomarkers of rejection and allograft outcome in kidney transplantation. Elevated urinary CXCL10 levels have been associated with acute rejection (AR) and may predict allograft failure. We examined the correlation of miRNA, CXCL10 levels and immunosuppressive drug exposure with AR and graft function in kidney transplant recipients. Experimental Approach Eighty de novo kidney transplant recipients were recruited from four European centres. All patients received tacrolimus, mycophenolate mofetil, and methylprednisolone. Urinary pellet expression of miR-142-3p, miR-210-3p, and miR-155-5p was assessed by qPCR and urinary CXCL10 levels by ELISA at the 1st week and the 1st, 2nd, 3rd and 6th month post-transplantation. Key Results Eight patients experienced AR. Before and during AR, patients showed a significant increase of urinary miR-142-3p, miR-155-5p, and CXCL10 levels and a decrease of miR-210-3p levels. Receiver Operating Characteristic curve analysis showed that miR-155-5p (AUC=0.875; P=0.046) and CXCL10 (AUC=0.865; P=0.029) had excellent capacity to discriminate between rejectors and non-rejectors. The optimal cut-off values for the prognosis of AR were 0.51, with 85% sensitivity and 86% specificity for miR-155-5p and 84.73 pg/ml, with 84% sensitivity and 80% specificity for CXCL10. miR-155-5p and CXCL10 levels correlated with glomerular filtration rate. Levels of both biomarkers normalised after recovery of graft function. Conclusions and Implications The regular early post-transplantation monitoring of urinary miR-155-5p and CXCL10 can help in the prognosis of AR and graft dysfunction. Large prospective randomised multicentre trials are warranted to refine our cut-off values and validate the clinical usefulness of these biomarkers.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1111/bcp.13399

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.